Novo Nordisk<\/a> Foundation headquarters in Copenhagen.<\/p>\nThe day-long event in mid-May brought together 28 experts in the fields of AI, biology, regenerative medicine, venture, and company building for a day-long symposium on Engineering Cell Fate, something Breakstone believes will become the next AlphaFold moment for biology.<\/p>\n
\u201cWe are using AI to understand how cells communicate and to make new tissue,\u201d Breakstone said during a talk with Olivier Pourquie at the symposium.<\/p>\n
![\"Vitaly](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/06\/725257.jpeg\"\/)
Vitaly Formin, CEO of Numenos, hopes to \u2018cure everything, starting with cancer.\u2019 (credit: Leitorp + Vadskaer for Cellular intelligence)<\/p>\n
During the talk with Pourquie, Breakstone pointed to Parkinson\u2019s, Type 1 diabetes, epilepsy, and macular degeneration as other diseases that could be helped by their technology.<\/p>\n
Parkinson\u2019s disease affects millions of people worldwide, and current treatments primarily focus on managing symptoms rather than replacing the neurons lost to the condition.<\/p>\n
The STEM\u2011PD therapy is designed to introduce new dopamine\u2011producing cells, offering a regenerative approach that differs fundamentally from existing therapies.<\/p>\n
\u201cBringing AI into this world has been challenging; we are trying to create noise in the room, to create a notion of urgency in this ecosystem,\u201d Breakstone told the Magazine at the symposium.<\/p>\n
According to him, much of the technology was already there to integrate AI into the field of biology. \u201cThe issue isn\u2019t convincing people, it\u2019s executing,\u201d he said.<\/p>\n
A Danish home\u00a0<\/strong><\/p>\nDenmark\u2019s capital has a long history of producing results in therapeutics, and Breakstone explained that the company \u201clanded in a perfect home\u201d when they signed the deal with Novo Nordisk. \u201cWe are infusing AI into the culture of this ecosystem here in Copenhagen.\u201d<\/p>\n
Biology is very complex, and for decades, finding cures to debilitating diseases has taken decades and cost millions of dollars. In recent years, the application of AI into the field has made significant strides, including allowing scientists to predict how cells would respond to external cues.<\/p>\n
With Novo Nordisk\u2019s clinical\u2011stage cell therapy program, Cellular Intelligence plans to apply its AI foundation model, which is trained on millions of cellular perturbation conditions, to accelerate the development and manufacturing of the therapy toward commercialization.<\/p>\n
The company says its platform can compress traditional cell\u2011therapy timelines and reduce production costs, a key barrier to commercializing complex regenerative\u2011medicine products.<\/p>\n
The program\u2019s progress will be closely watched as researchers and industry leaders evaluate the potential of AI\u2011supported development pipelines to accelerate the arrival of next\u2011generation treatments.<\/p>\n
\u201cIt can speed things up,\u201d said Jens Nielsen, CEO of BioInnovation Institute (BII), Copenhagen, Denmark, and professor of systems biology at Chalmers University of Technology, Gothenburg, Sweden.<\/p>\n
Speaking to the Magazine on the sidelines of the symposium, Nielsen said that AI can help speed up \u201cpreparations, analysis, development time and cost.\u201d<\/p>\n
Cellular Intelligence, he said, \u201cis infusing technology to biology, which is super complex.\u201d<\/p>\n
The BII is a life science and DeepTech innovation institute in Copenhagen. It supports over 130 startups that have collectively raised over \u20ac1 billion in external funding.<\/p>\n
According to Nielsen, \u201cIsrael has excellent innovation and drive. We want to capture that for Copenhagen. The fusion of our history and that technology will enrich the ecosystem.\u201d<\/p>\n
Nielsen, who has visited Israel numerous times and has spoken to key stakeholders, explained that while Israel has a lot of biotech companies, there are fewer health-tech companies. Denmark, he said, \u201cdespite its small size, has a lot to offer in terms of drug development competence.\u201d<\/p>\n
It\u2019s personal<\/strong><\/p>\nFor Breakstone, finding a cure for Parkinson\u2019s is personal. Yet, it\u2019s not only Parkinson\u2019s that Cellular Intelligence hopes to find a cure for.<\/p>\n
\u201cCancer is really interesting. We are having initial thoughts about the disease and are optimistic about learning how cancer evolves and behaves.\u201d<\/p>\n
Vitaly Formin, CEO of Numenos, also hopes to use AI to match drugs to biology and thereby \u201ccure everything, starting with cancer.\u201d<\/p>\n
According to the company, its CURE platform integrates and analyzes clinical trial data, revealing valuable insights that guide decision-making and patient stratification.<\/p>\n
With a diverse team made up of entrepreneurs, biologists, physicists, and AI specialists, the company specializes in detecting biomarkers early in clinical trial development to allow for cheaper and more successful phase three clinical trial design.<\/p>\n
Formin noted that Numenos aims to match drugs to a person\u2019s biology and predict what the drug will do.<\/p>\n
\u201cWe look at the human as a whole biological system. We find the law of one disease and apply it to others,\u201d he said on the sidelines of the symposium. \u201cCancer is a process of life. You can take data from a specific cancer and apply it to other diseases. The data is interconnected.\u201d<\/p>\n
Formin believes that with the help of AI, patients would have extended time to speak with their physician. \u201cWe want every patient to have a Ph.D in their disease,\u201d he said.<\/p>\n
\u201cThe future of biotech will change human revolution,\u201d Formin stated.<\/p>\n
Not destiny, but designed<\/p>\n
AI\u2011native platforms are not just accelerating stem\u2011cell therapy; they are now redefining what is scientifically possible. Cellular Intelligence\u2019s fusion of computational power, biological insight, and global collaboration signals a turning point where living medicines can now be engineered with the same intentionality as any other technology.<\/p>\n
What once depended on slow intuition is shifting toward predictive, data\u2011driven design, opening the door to therapies that are scalable, precise, and personalized.<\/p>\n
The momentum building in Copenhagen, Boston<\/a>, and Israel shows that this is no isolated trend but the emergence of a new biomedical architecture.<\/p>\nIt is one where regenerative medicine is guided by algorithms that learn, adapt, and improve. If the field succeeds, diseases long considered intractable may become tractable, and conditions managed for decades may finally be cured.<\/p>\n
As cellular intelligence guides the body toward healing, AI is guiding modern medicine toward a future where care is smarter, gentler, and profoundly more effective.<\/p>\n
As Breakstone puts it, \u201cBiology is no longer destiny, but designed.\u201d<\/p>\n
The writer was a guest of the symposium.<\/p>\n","protected":false},"excerpt":{"rendered":"Cells have always been the body\u2019s original intelligence system \u2013 sensing, adapting, repairing, and communicating with remarkable precision.…\n","protected":false},"author":2,"featured_media":532991,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[78],"tags":[289,8108,18049,382,18,135,188128,19,17,123176],"class_list":["post-532990","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-artificial-intelligence","tag-biology","tag-boston","tag-denmark","tag-eire","tag-health","tag-hi-tech","tag-ie","tag-ireland","tag-parkinson"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116741651093002655","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/532990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=532990"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/532990\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/532991"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=532990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=532990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=532990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Breakstone](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/06\/725256.jpeg\"\/)
Breakstone (R) with jens Nielsen, CEO of Copenhagen\u2019s BioInnovation Institute, during a break in the symposium. (credit: Leitorp + Vadskaer for Cellular intelligence)<\/p>\n